Los Angeles Capital Management LLC Has $2.07 Million Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Journal Important Web

Los Angeles Capital Management LLC impaired its function in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 64.2% during the prototypal quarter, according to the consort in its most past 13F filing with the SEC. The money owned 127,551 shares of the company’s hit after commerce 228,979 shares during the quarter. Los Angeles Capital Management LLC owned roughly 0.29% of Y-mAbs Therapeutics worth $2,074,000 as of its most past filing with the SEC.

Other inclose assets and another institutionalised investors hit also bought and oversubscribed shares of the company. China Universal Asset Management Co. Ltd. acquired a newborn wager in Y-mAbs Therapeutics in the 4th lodge valued at roughly $34,000. Tower Research Capital LLC TRC upraised its function in Y-mAbs Therapeutics by 345.4% in the 4th quarter. Tower Research Capital LLC TRC today owns 6,686 shares of the company’s hit valued at $46,000 after purchase an added 5,185 shares during the terminal quarter. Bailard Inc. acquired a newborn function in shares of Y-mAbs Therapeutics during the 4th lodge worth roughly $115,000. SG Americas Securities LLC accumulated its function in shares of Y-mAbs Therapeutics by 17.5% during the 4th quarter. SG Americas Securities LLC today owns 21,559 shares of the company’s hit worth $147,000 after purchase an added 3,210 shares during the terminal quarter. Finally, Mirae Asset Global Investments Co. Ltd. accumulated its function in shares of Y-mAbs Therapeutics by 4.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. today owns 26,090 shares of the company’s hit worth $178,000 after purchase an added 1,089 shares during the terminal quarter. Institutional investors and inclose assets possess 70.85% of the company’s stock.

Analysts Set New Price Targets

Several investigate analysts hit weighed in on the company. HC Wainwright boosted their toll direct on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the hit a “buy” judgement in a investigate inform on Monday, May 13th. BMO Capital Markets boosted their toll direct on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the hit an “outperform” judgement in a investigate inform on Monday, March 4th. Finally, Canaccord Genuity Group boosted their toll direct on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the hit a “buy” judgement in a investigate inform on Monday, March 4th. Two assets analysts hit rated the hit with a delude judgement and quaternary hit issued a acquire judgement to the company. Based on accumulation from MarketBeat, Y-mAbs Therapeutics currently has a consensus judgement of “Hold” and an cipher toll direct of $17.33.

Get Our Latest Research Report on YMAB

Y-mAbs Therapeutics Trading Up 2.1 %

Shares of NASDAQ YMAB unsealed at $12.00 on Friday. Y-mAbs Therapeutics, Inc. has a 12 period baritone of $4.60 and a 12 period broad of $20.90. The hit has a 50 period agitated cipher of $13.36 and a 200-day agitated cipher of $12.59.

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) terminal issued its earnings results on Tuesday, May 7th. The consort reportable ($0.15) EPS for the quarter, absent the consensus judge of ($0.12) by ($0.03). The playing had income of $19.93 meg for the quarter, compared to the consensus judge of $22.06 million. Y-mAbs Therapeutics had a perverse convey on justness of 21.40% and a perverse gain edge of 25.64%. On average, equities analysts look that Y-mAbs Therapeutics, Inc. module place -0.45 earnings per deal for the underway year.

Insider Activity at Y-mAbs Therapeutics

In attendant news, insider Thomas Gad oversubscribed 7,351 shares of the business’s hit in a dealings on Thursday, May 23rd. The hit was oversubscribed at an cipher toll of $13.00, for a amount continuance of $95,563.00. Following the termination of the sale, the insider today direct owns 232,681 shares in the company, valued at roughly $3,024,853. The dealings was unconcealed in a filing with the Securities & Exchange Commission, which is reachable finished the SEC website. In another news, CFO Bo Kruse oversubscribed 31,371 shares of the company’s hit in a dealings on Friday, May 31st. The hit was oversubscribed at an cipher toll of $12.07, for a amount dealings of $378,647.97. Following the termination of the sale, the honcho business tar today direct owns 210,877 shares in the company, valued at roughly $2,545,285.39. The dealings was unconcealed in a filing with the SEC, which is reachable finished this hyperlink. Also, insider Thomas Gad oversubscribed 7,351 shares of the company’s hit in a dealings on Thursday, May 23rd. The shares were oversubscribed at an cipher toll of $13.00, for a amount continuance of $95,563.00. Following the sale, the insider today owns 232,681 shares of the company’s stock, valued at $3,024,853. The revealing for this understanding crapper be institute here. Insiders oversubscribed 99,444 shares of consort hit worth $1,203,925 in the terminal cardinal days. 21.50% of the hit is owned by consort insiders.

Y-mAbs Therapeutics Company Profile

(Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the utilization and development of antibody supported therapeutic products for the communication of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in compounding with granulocyte-macrophage colony-stimulating bourgeois for the communication of medicine patients with relapsed or disobedient high-risk neuroblastoma in the pearl or pearl marrow.

Recommended Stories

Receive News & Ratings for Y-mAbs Therapeutics Daily – Enter your telecommunicate come beneath to obtain a apothegmatic regular unofficial of the stylish programme and analysts’ ratings for Y-mAbs Therapeutics and attendant companies with MarketBeat.com’s FREE regular telecommunicate newsletter.